An esterase-activatable curcumin prodrug for tumor-targeting therapy

Area of Science:

• Oncology
• Drug Delivery
• Biomedical Engineering

Background:

• Tumor-targeting therapy is crucial for increasing drug accumulation in tumors and minimizing side effects in healthy tissues.
• Curcumin exhibits therapeutic potential but suffers from poor bioavailability and tumor specificity.
• Developing targeted drug delivery systems is essential for effective cancer treatment.

Purpose of the Study:

• To develop an esterase-activatable curcumin prodrug, Cur-RGD, for enhanced tumor-targeting therapy.
• To investigate the efficacy of Cur-RGD in improving drug accumulation and therapeutic effects in tumors.
• To leverage the RGD peptide for active tumor targeting and esterase for triggered drug release.

Main Methods:

• Synthesis of the curcumin prodrug Cur-RGD.
• Incorporation of the tumor-targeting RGD peptide into the prodrug structure.
• Evaluation of esterase-triggered drug release in situ.
• Assessment of tumor accumulation and therapeutic efficacy of Cur-RGD.

Main Results:

• The developed Cur-RGD prodrug demonstrated effective tumor targeting.
• Esterase activation led to in situ drug release within the tumor microenvironment.
• Cur-RGD significantly improved curcumin accumulation in tumors compared to free curcumin.
• Enhanced therapeutic effects were observed in tumor models treated with Cur-RGD.

Conclusions:

• The esterase-activatable curcumin prodrug Cur-RGD represents a promising strategy for tumor-targeting therapy.
• The combination of RGD peptide targeting and esterase-triggered release enhances drug delivery to tumors.
• Cur-RGD offers a potential approach to improve curcumin's efficacy while reducing systemic toxicity.